Vogiatzi, Fotini <br/><br/>
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.  [electronic resource] 

 -  Blood  08 2019 
 - 713-716 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood.2019000904  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Child<br/>Child, Preschool<br/>Female<br/>Humans<br/>Male<br/>Neoplasm, Residual--drug therapy<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Treatment Outcome